

DATE: April 1st, 2020
TO: All Well Sense Health Plan Providers
FROM: Well Sense Health Plan
SUBJECT: **Policy and Prior Authorization Program Changes**
PRODUCT: *WellSense*

Pharmacy Benefit Updates

The following drug(s) will require prior authorization under specific clinical pharmacy policies effective June 1, 2020:

- Trikafta
- Rinvoq
- Evenity
- Xembify

The following drug(s) will be Non-Preferred effective June 1, 2020

- Reyvow
- Nourianz
- Aklief
- Tracleer
- Isotretinoin oral
- Zenatane
- Amzeeq
- Rybelsus
- Vumerity
- Forteo

The following drug(s) will be covered without a prior authorization effective June 1, 2020:

- Jynneos

The following drug(s) will have coverage changes effective June 1, 2020

- Topical Tretinoin products: Prior authorization required for ages > 26 years

The following clinical policies have been updated; these changes are effective June 1, 2020:

Provider Communication



- Asthma-Allergy Monoclonal Antibodies
- Natpara
- Korlym
- Cholbam
- Sublingual Immunotherapy
- Cerdelga
- Entresto
- Duchenne Muscular Atrophy
- GnRH Agents
- Tranxemic Acid
- Erythropoiesis Stimulating Agents
- Daraprim
- Brineura
- Restasis, Xiidra
- Xeljanz
- Pulmonary Hypertension

Please find all [prior authorization forms](#) here.

Updated policies can be accessed next to the drug name in the [drug search tool](#). Policies will be available online 30 days prior to their effective date.